Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
07
2020
revised:
17
11
2020
accepted:
19
11
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Kaposi sarcoma is a rare vascular mesenchymal neoplasm, associated with Human Herpes Virus 8 (HHV8). Gout is a condition clinically characterized by recurrent flares of arthritis and hyperuricemia. Following our clinical impression that patients with classical Kaposi sarcoma (CKS) have a high rate of gout, we explored this in a retrospective manner. All consecutive patients diagnosed with sarcoma or carcinosarcoma within a single tertiary center between 1/2012-12/2017 were identified through the pathology department database. A cohort of CKS patients was compared with the non-Kaposi sarcoma and carcinosarcoma cohort. Data were extracted from patients' electronic medical records. Patients younger than 18 and patients without clinical data available were excluded. Association between diagnosis of gout and CKS was assessed and adjusted for risk factors. Three hundred and sixty-one patients were eligible for this analysis, 61 were diagnosed with CKS and 300 with other types of sarcoma. We found a higher incidence of gout in CKS patients, 11/61 (18%) patients, compared with 8/300 (2.6%) with other types of sarcoma, odds ratio (OR) 8.0 ( We have demonstrated a statistically significant association between gout and CKS. As risk factors for gout were accounted for, this association may be explained by HHV8 immune-related effects. This should be further explored in vitro and in population-based studies.
Sections du résumé
BACKGROUND
BACKGROUND
Kaposi sarcoma is a rare vascular mesenchymal neoplasm, associated with Human Herpes Virus 8 (HHV8). Gout is a condition clinically characterized by recurrent flares of arthritis and hyperuricemia. Following our clinical impression that patients with classical Kaposi sarcoma (CKS) have a high rate of gout, we explored this in a retrospective manner.
METHODS
METHODS
All consecutive patients diagnosed with sarcoma or carcinosarcoma within a single tertiary center between 1/2012-12/2017 were identified through the pathology department database. A cohort of CKS patients was compared with the non-Kaposi sarcoma and carcinosarcoma cohort. Data were extracted from patients' electronic medical records. Patients younger than 18 and patients without clinical data available were excluded. Association between diagnosis of gout and CKS was assessed and adjusted for risk factors.
RESULTS
RESULTS
Three hundred and sixty-one patients were eligible for this analysis, 61 were diagnosed with CKS and 300 with other types of sarcoma. We found a higher incidence of gout in CKS patients, 11/61 (18%) patients, compared with 8/300 (2.6%) with other types of sarcoma, odds ratio (OR) 8.0 (
CONCLUSIONS
CONCLUSIONS
We have demonstrated a statistically significant association between gout and CKS. As risk factors for gout were accounted for, this association may be explained by HHV8 immune-related effects. This should be further explored in vitro and in population-based studies.
Identifiants
pubmed: 33519292
doi: 10.1155/2020/8844970
pmc: PMC7817232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8844970Informations de copyright
Copyright © 2020 Assaf Moore et al.
Déclaration de conflit d'intérêts
Assaf Moore declares honoraria from Merck, Roche. Idit Perez, Lilach Yosef, Daniel A. Goldstein, Suzanna Horn, and Yonatan Edel declare no conflicts of interest to disclose. Hadar Goldvaser declares honoraria from Novartis, Roche, Pfizer, Oncotest. Alona Zer declares advisory role from Astra Zeneca, Merck, Roche; honoraria from Astra Zeneca, Bristol Myers Squibb, Merck, Roche; and research funding from Bristol Myers Squibb.
Références
Clin Microbiol Infect. 2003 Apr;9(4):274-9
pubmed: 12667236
Rheum Dis Clin North Am. 2006 May;32(2):255-73, v
pubmed: 16716879
Cell Host Microbe. 2011 May 19;9(5):363-75
pubmed: 21575908
J Hum Virol. 1998 Mar-Apr;1(3):193-9
pubmed: 10195242
Lancet. 1990 Jan 20;335(8682):123-8
pubmed: 1967430
Autoimmun Rev. 2013 Mar;12(5):554-7
pubmed: 23092582
J Inflamm Res. 2011;4:39-49
pubmed: 22096368
Arthritis Rheum. 2011 Oct;63(10):3136-41
pubmed: 21800283
AIDS. 1998 Oct 22;12(15):2067-72
pubmed: 9814876
Nat Rev Immunol. 2004 Jul;4(7):499-511
pubmed: 15229469
J Rheumatol. 2002 Nov;29(11):2403-6
pubmed: 12415600
Nat Commun. 2012 Apr 03;3:764
pubmed: 22473008
Nat Immunol. 2006 Feb;7(2):131-7
pubmed: 16424890
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Arthritis Rheum. 1977 Apr;20(3):895-900
pubmed: 856219
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Nat Immunol. 2001 Aug;2(8):675-80
pubmed: 11477402
J Virol. 2008 Jun;82(11):5440-9
pubmed: 18367536
Transplant Rev (Orlando). 2008 Oct;22(4):252-61
pubmed: 18656341
J Infect Dis. 1998 Jun;177(6):1715-8
pubmed: 9607855
J Natl Cancer Inst. 2002 Nov 20;94(22):1712-8
pubmed: 12441327
Arthritis Care Res (Hoboken). 2013 Jan;65(1):127-32
pubmed: 22778033
J Gen Virol. 2006 Jul;87(Pt 7):1781-1804
pubmed: 16760382
Science. 1996 Dec 6;274(5293):1739-44
pubmed: 8939871
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
Crit Rev Oncol Hematol. 2008 Dec;68(3):242-9
pubmed: 18657433
Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3435-43
pubmed: 19064559
J Rheumatol. 2000 Apr;27(4):1045-50
pubmed: 10782835
Proc Natl Acad Sci U S A. 2017 May 23;114(21):5485-5490
pubmed: 28484006
Cancer. 2006 Nov 1;107(9):2282-90
pubmed: 16998933
Ann Rheum Dis. 2016 Apr;75(4):755-62
pubmed: 25649144
Metabolism. 2012 Apr;61(4):512-8
pubmed: 22001332
Blood. 2005 Oct 15;106(8):2790-7
pubmed: 15976177
Arthritis Rheumatol. 2014 Mar;66(3):560-8
pubmed: 24574215
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879